Oncology Pharma Stock Price Patterns
| ONPH Stock | USD 0.01 0 36.25% |
Momentum 45
Impartial
Oversold | Overbought |
Using Oncology Pharma hype-based prediction, you can estimate the value of Oncology Pharma from the perspective of Oncology Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Oncology Pharma to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Oncology because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Oncology Pharma after-hype prediction price | USD 0.006553 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Oncology |
Oncology Pharma After-Hype Price Density Analysis
As far as predicting the price of Oncology Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Oncology Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Oncology Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Oncology Pharma Estimiated After-Hype Price Volatility
In the context of predicting Oncology Pharma's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Oncology Pharma's historical news coverage. Oncology Pharma's after-hype downside and upside margins for the prediction period are 0.00 and 25.60, respectively. We have considered Oncology Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Oncology Pharma is out of control at this time. Analysis and calculation of next after-hype price of Oncology Pharma is based on 3 months time horizon.
Oncology Pharma Pink Sheet Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Oncology Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncology Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Oncology Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.51 | 25.59 | 0.00 | 0.07 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.01 | 0.01 | 28.49 |
|
Oncology Pharma Hype Timeline
Oncology Pharma is now traded for 0.01. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.07. Oncology is projected to increase in value after the next headline, with the price projected to jump to 0.006553 or above. The average volatility of media hype impact on the company the price is insignificant. The price growth on the next news is estimated to be 28.49%, whereas the daily expected return is now at 2.51%. The volatility of related hype on Oncology Pharma is about 98460.95%, with the expected price after the next announcement by competition of -0.06. Oncology Pharma currently holds 205.9 K in liabilities. Oncology Pharma has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncology Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Oncology Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncology Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncology to invest in growth at high rates of return. When we think about Oncology Pharma's use of debt, we should always consider it together with cash and equity.Given the investment horizon of 90 days the next projected press release will be uncertain. Check out Oncology Pharma Basic Forecasting Models to cross-verify your projections.Oncology Pharma Related Hype Analysis
Having access to credible news sources related to Oncology Pharma's direct competition is more important than ever and may enhance your ability to predict Oncology Pharma's future price movements. Getting to know how Oncology Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Oncology Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PANC | Panacos Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BTTX | Better Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TLOG | TetraLogic Pharmaceuticals Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ARNI | Arno Therapeutics | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 100.00 | |
| AMPE | Ampio Pharm | (0.26) | 1 per month | 50.93 | 0.33 | 3,233 | (96.29) | 5,924 | |
| CALA | Calithera Biosciences | 0.00 | 0 per month | 21.14 | 0.15 | 100.00 | (50.00) | 280.00 | |
| WUHN | Wuhan General Gr | 0.00 | 1 per month | 0.00 | 0.13 | 0.00 | 0.00 | 300.00 | |
| IVBT | Innovation1 Biotech | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BXRXQ | Baudax Bio | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| INND | Innerscope Advertising Agency | 0.00 | 0 per month | 0.00 | (0.01) | 25.00 | (18.18) | 64.44 |
Oncology Pharma Additional Predictive Modules
Most predictive techniques to examine Oncology price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Oncology using various technical indicators. When you analyze Oncology charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Oncology Pharma Predictive Indicators
The successful prediction of Oncology Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Oncology Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Oncology Pharma based on analysis of Oncology Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Oncology Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Oncology Pharma's related companies.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Complementary Tools for Oncology Pink Sheet analysis
When running Oncology Pharma's price analysis, check to measure Oncology Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Pharma is operating at the current time. Most of Oncology Pharma's value examination focuses on studying past and present price action to predict the probability of Oncology Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Pharma's price. Additionally, you may evaluate how the addition of Oncology Pharma to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |